GSK plc (GSK)
After hours:
| Previous Close | 30.01 |
| Open | 29.45 |
| Bid | 29.45 x 1100 |
| Ask | 29.65 x 2200 |
| Day's Range | 29.09 - 29.63 |
| 52 Week Range | 29.09 - 46.97 |
| Volume | |
| Avg. Volume | 6,519,685 |
| Market Cap | 59.322B |
| Beta (5Y Monthly) | 0.26 |
| PE Ratio (TTM) | 11.47 |
| EPS (TTM) | 2.56 |
| Earnings Date | Feb 01, 2017 - Feb 06, 2017 |
| Forward Dividend & Yield | 2.48 (8.46%) |
| Ex-Dividend Date | May 19, 2022 |
| 1y Target Est | 54.29 |
- Sky News
GSK poaches Burberry CFO to create all-female top team
GSK, the FTSE-100 pharmaceuticals giant, has poached Burberry Group's finance chief to create a rare all-female executive leadership team in London's blue-chip share index. Sky News has learnt that GSK could announce as soon as Monday morning that it has recruited Julie Brown to replace Iain Mackay, who has served as its chief financial officer since 2019. The appointment of Ms Brown comes during a period of seismic change for GSK, which demerged its consumer healthcare business - now called Haleon - in a £30bn deal in July.
- Reuters
UPDATE 1-GSK poaches Burberry CFO Julie Brown to create all-female top team - Sky News
British drugmaker GSK plc has poached Burberry Group's finance chief to create a rare all-female executive leadership team, Sky News reported on Saturday. GSK could announce as soon as Monday morning that it has recruited Julie Brown to replace Iain Mackay, who has served as its chief financial officer since 2019, the report added. On Friday, Burberry announced that its finance chief Julie Brown will step down in April 2023 after more than five years in the role.
- Zacks
Spero (SPRO) Skyrockets 168% on Licensing Deal With GSK
The exclusive licensing agreement with GSK will fund Spero's (SPRO) existing operations and extend its current cash runway beyond 2024.
